| abstract |
The present invention relates to agents and methods for the diagnosis, prognosis and treatment of cancer. Specifically, the present invention relates to a transmembrane superfamily member 6 (TM4SF6), a synaptophysin-like protein. (SYPL), Stomatin-like 2 (STOML2), Ras-related GTP-binding protein RAGA), nucleotide-sensitive chloride channel 1A (CLNS1A), prion protein (p27-30) (PRNP), guanine nucleotide-binding protein beta2-like 1 (GNB2L1), guanine nucleotide-binding protein 4 (GNG4), integral membrane protein 2B (ITM2B), integral membrane protein 1 (ITM1), membrane Penetrating 9 Superfamily member 2 (TM9SF2), opiate receptor-like 1 protein (OPRL1), low-density lipoprotein receptor-related protein 4 (LRP4), human glomerular epithelial protein 1 (GLEPP1), toll-like receptor 3 (TLR3), and / or zona pellucida glycoprotein 3A (ZP3) -encoding nucleic acid and amino acid sequences, both early and late nonsteroid-specific cancer diagnosis and cancer prognosis , For use in screening for agents that modulate gene expression and / or biological activity of the protein. The present invention further includes gene expression and / or biology of the protein, including the use of agents identified in the screening assays described herein, vector delivery of antisense polynucleotide sequences, and antibody targeting of the protein. Relates to biological techniques designed to inhibit biological activity. In a specific embodiment, said protein is from a human. |